General Biotechnologies
General Biotechnologies manufactures peptide therapeutics at a fraction of current costs by genetically programming edible microbes to synthesize and deliver complex molecules orally. Its flagship program, GB-03 Regenesis, is the world's first oral GLP-1 delivered as a single-dose daily powder with no cold chain or needles, targeting a price cap below $5 per dose. The company also operates a reformulation platform that revives discontinued peptide assets as oral drugs.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Peptide therapeutics, including GLP-1 drugs, are typically administered via injection, requiring cold-chain logistics, trained healthcare professionals, and frequent clinic visits. This limits patient adherence, increases costs, and restricts access for populations in remote or resource-limited settings.
Solution
General Biotechnologies genetically programs edible microbes to act as both a peptide factory and a delivery vehicle, synthesizing complex molecules on demand and protecting them through the digestive tract. The company's platform deciphers the biosynthetic machinery of living cells and rewrites their code to produce clinically validated peptides at a fraction of current manufacturing costs. Its flagship program, GB-03 Regenesis, is the world's first oral GLP-1, delivered as a single-dose daily powder that requires no needles and no cold chain. The company also operates a reformulation platform, GB-04, that revives discontinued but clinically proven peptide assets by synthesizing them inside its programmable microbes and conducting preclinical studies to demonstrate oral bioavailability.
Target Audience
Primary customers are pharmaceutical companies holding discontinued peptide assets, as well as healthcare providers and patients seeking affordable, needle-free alternatives to injectable peptide drugs like GLP-1 receptor agonists.
Features
- Genetically programmed edible microbes that synthesize and deliver peptide therapeutics in a single organism
- Oral delivery format that protects peptides from stomach acid and enzymes, lab-validated at 90% protection for GLP-1
- Single-dose daily powder formulation with no cold-chain or injection requirements, targeting a price cap below $5 per dose
- Reformulation platform for discontinued peptide assets, offering option agreements and right-of-first-refusal to original developers
- Preclinical PK/PD animal study capabilities to demonstrate drug absorption and provide manufacturing cost reports
- Manufacturing partnership for a 10,000 L robotic cGMP-grade pilot production run
- In development with 9 peptide variants in preclinical testing, including novel variants and approved GLP-1s